Thermo Fisher Authorizes $750M Stock Repurchase Program, Notes Offering | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher today said that its board of directors has authorized a plan to repurchase $750 million of the firm's common stock.

The one-year plan would involve the firm acquiring shares of its common stock on the open market or in negotiated transactions.

Thermo Fisher said that it will offer approximately $750 million of senior notes to refinance outstanding indebtedness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.